Ensifentrine in COPD Patients Taking Long-acting Bronchodilators: A Pooled Post-hoc Analysis of the ENHANCE-1/2 Studies

Overview

Journal Chron Respir Dis

Publisher Sage Publications

Date 2025 Jan 24

PMID 39854278

Authors

Mark Dransfield

Nathaniel Marchetti

Ravi Kalhan

Daniel Reyner

Amy L Dixon

Tara Rheault

Kathleen Ann Rickard

Antonio Anzueto

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy and safety of ensifentrine, a novel PDE3/PDE4 inhibitor, were previously evaluated in the ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) trials. Here, we present a pooled post-hoc subgroup analysis of patients according to background chronic obstructive pulmonary disease (COPD) maintenance medication regimens.

Objective: This analysis aimed to explore the efficacy and safety of ensifentrine in patients receiving long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists with inhaled corticosteroids (LABA + ICS).

Methods: Eligible patients had moderate to severe COPD, were aged 40-80 years, and were symptomatic at randomization. Patients were randomized 5:3, receiving twice-daily ensifentrine 3 mg or placebo via standard jet nebulizer over 24 weeks.

Results: The pooled post-hoc analysis included 485 LAMA patients and 272 LABA + ICS patients. Ensifentrine showed lung function improvement over placebo at week 12, including average FEV AUC in the LAMA (placebo-corrected least squares mean change from baseline [LSMC], 92 mL; 95% CI, 54, 131; < 0.001) and LABA + ICS subgroups (LSMC, 74 mL; 95% CI, 27, 121; = 0.002). Ensifentrine reduced the rate and risk of exacerbations in both LAMA (48% and 50%, respectively) and LABA + ICS (51% and 56%, respectively) subgroups. Ensifentrine-treated patients reported improvement in symptoms and quality of life over 24 weeks. The safety profile of ensifentrine in each subgroup was similar to the profile in the pooled modified intention-to-treat population.

Conclusions: Nebulized ensifentrine offers a novel non-steroidal anti-inflammatory and bronchodilator treatment added to existing LAMA or LABA + ICS treatment options in patients with moderate to severe, symptomatic COPD.

References

Oba Y, Lone N . Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2012; 7(1):13-24. DOI: 10.1177/1753465812466167. View

Watz H, Rickard K, Rheault T, Bengtsson T, Singh D . Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis. Int J Chron Obstruct Pulmon Dis. 2020; 15:2199-2206. PMC: 7502392. DOI: 10.2147/COPD.S263025. View

Anzueto A, Barjaktarevic I, Siler T, Rheault T, Bengtsson T, Rickard K . Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023; 208(4):406-416. PMC: 10449067. DOI: 10.1164/rccm.202306-0944OC. View

Challiss R, Adams D, Mistry R, Nicholson C . Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle. Br J Pharmacol. 1998; 124(1):47-54. PMC: 1565354. DOI: 10.1038/sj.bjp.0701792. View

Morita H, Matsumoto K, Saito H . Biologics for allergic and immunologic diseases. J Allergy Clin Immunol. 2022; 150(4):766-777. DOI: 10.1016/j.jaci.2022.08.009. View

Chen S, Small M, Lindner L, Xu X . Symptomatic burden of COPD for patients receiving dual or triple therapy. Int J Chron Obstruct Pulmon Dis. 2018; 13:1365-1376. PMC: 5927353. DOI: 10.2147/COPD.S163717. View

de Boer J, Philpott A, van Amsterdam R, Shahid M, Zaagsma J, Nicholson C . Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol. 1992; 106(4):1028-34. PMC: 1907637. DOI: 10.1111/j.1476-5381.1992.tb14451.x. View

Calverley P, Rabe K, Goehring U, Kristiansen S, Fabbri L, Martinez F . Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374(9691):685-94. DOI: 10.1016/S0140-6736(09)61255-1. View

Lange P, Ahmed E, Lahmar Z, Martinez F, Bourdin A . Natural history and mechanisms of COPD. Respirology. 2021; 26(4):298-321. DOI: 10.1111/resp.14007. View

10.

Franciosi L, Diamant Z, Banner K, Zuiker R, Morelli N, Kamerling I . Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2014; 1(9):714-27. DOI: 10.1016/S2213-2600(13)70187-5. View

11.

Milara J, Navarro A, Almudever P, Lluch J, Morcillo E, Cortijo J . Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011; 41(4):535-46. DOI: 10.1111/j.1365-2222.2011.03715.x. View

12.

Moretz C, Hahn B, White J, Hunter A, Essoi B, Elliott C . Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Int J Chron Obstruct Pulmon Dis. 2020; 15:2715-2725. PMC: 7605915. DOI: 10.2147/COPD.S265037. View

13.

Schmidt D, Watson N, Dent G, Ruhlmann E, Branscheid D, Magnussen H . The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br J Pharmacol. 2001; 131(8):1607-18. PMC: 1572487. DOI: 10.1038/sj.bjp.0703725. View

14.

Kerkhof M, Voorham J, Dorinsky P, Cabrera C, Darken P, Kocks J . The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline. Int J Chron Obstruct Pulmon Dis. 2020; 15:1909-1918. PMC: 7418151. DOI: 10.2147/COPD.S253812. View

15.

Banner K, Press N . Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol. 2009; 157(6):892-906. PMC: 2737648. DOI: 10.1111/j.1476-5381.2009.00170.x. View

16.

Rabe K, Martinez F, Ferguson G, Wang C, Singh D, Wedzicha J . Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020; 383(1):35-48. DOI: 10.1056/NEJMoa1916046. View

17.

Gibson P, Yang I, Upham J, Reynolds P, Hodge S, James A . Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390(10095):659-668. DOI: 10.1016/S0140-6736(17)31281-3. View

18.

Thomas B, Koh M, OCallaghan C, Allen Jr J, Rutman A, Hirst R . Dysfunctional Bronchial Cilia Are a Feature of Chronic Obstructive Pulmonary Disease (COPD). COPD. 2021; 18(6):657-663. DOI: 10.1080/15412555.2021.1963695. View

19.

Raju S, Rasmussen L, Sloane P, Tang L, Libby E, Rowe S . Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice. Respir Res. 2017; 18(1):173. PMC: 5604356. DOI: 10.1186/s12931-017-0656-0. View

20.

Hurst J, Han M, Singh B, Sharma S, Kaur G, De Nigris E . Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022; 23(1):213. PMC: 9396841. DOI: 10.1186/s12931-022-02123-5. View